Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity

Ann Surg Oncol. 2007 Jul;14(7):2105-12. doi: 10.1245/s10434-007-9365-0. Epub 2007 Apr 25.

Abstract

Background: Isolated limb perfusion (ILP) with tumor necrosis factor alpha (TNF-alpha) and melphalan, followed by delayed surgical resection and adjuvant external-beam radiotherapy is a limb salvage treatment strategy for locally advanced soft tissue sarcomas. The long-term vascular side effects of this combined procedure were evaluated.

Methods: Thirty-two patients were treated for a locally advanced sarcoma of the upper (n = 5) or lower limb (n = 27). All patients underwent a noninvasive vascular work-up.

Results: Five patients underwent a leg amputation, in two cases due to critical leg ischemia 10 years after ILP. With a median follow-up of 88 (range, 17-159) months, none of the patients with a salvaged lower leg (n = 22) experienced peripheral arterial occlusive disease. Ankle-brachial index (ABI) measurements in the involved leg (median, 1.02; range, .50-1.20) showed a significant decrease compared with the contralateral leg (median, 1.09; range, .91-1.36, P = .001). Pulsatility index (PI) was decreased in the treated leg in 17 of 22 patients at the femoral level (median, 6.30; range, 2.1-23.9 vs. median, 7.35; range, 4.8-21.9; P = .011) and in 19 of 20 patients at popliteal level (median, 8.35; range, 0-21.4 vs. median, 10.95; range, 8.0-32.6; P < .0005). In patients with follow-up of >5 years, there was more often a decrease in ABI (P = .024) and PI at femoral level (P = .011).

Conclusions: ILP followed by resection and external-beam radiotherapy can lead to major late vascular morbidity that requires amputation. Objective measurements show a time-related decrease of ABI and femoral PI in the treated extremity.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amputation, Surgical
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Chemotherapy, Cancer, Regional Perfusion / adverse effects*
  • Extremities / blood supply
  • Female
  • Humans
  • Ischemia / etiology
  • Ischemia / surgery
  • Limb Salvage / methods
  • Male
  • Melphalan / administration & dosage
  • Middle Aged
  • Radiotherapy, Adjuvant / adverse effects*
  • Sarcoma / surgery
  • Sarcoma / therapy*
  • Soft Tissue Neoplasms / surgery
  • Soft Tissue Neoplasms / therapy*
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Vascular Diseases / etiology*
  • Vascular Diseases / surgery

Substances

  • Tumor Necrosis Factor-alpha
  • Melphalan